Observational Study
Copyright ©The Author(s) 2022.
World J Gastrointest Pharmacol Ther. Jul 5, 2022; 13(4): 47-56
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.47
Table 1 Demography, clinical and biochemical profile of all primary hyperparathyroidism patients
Parameters
n = 51
Age (yr)47.80 ± 14.51
Female gender31 (60.78%)
Sex (female: male)1.55:1 (female 31, male 20)
Bone pain28 (54.90%)
Fracture 04 (7.84%)
Pain abdomen22 (43.13%)
Nausea and vomiting16 (31.37%)
Weight loss12 (23.52%)
Fatigue and weakness25 (49.01%)
Anorexia 16 (31.37%)
Psychiatric features06 (11.76%)
Nephrolithiasis 17 (33.33%)
Nephrocalcinosis 11 (21.56%)
Cholelithiasis 04 (7.84%)
Serum creatinine (mg/dL)0.80 (0.63-1.14)
Serum corrected calcium(mg/dL)12.41 ± 1.58
Serum phosphorous (mg/dL)2.7 (2.2-3.17)
Serum magnesium (mg/dL)1.80 (1.7-2)
Serum albumin (g/dL)3.90 (3.5-4.2)
Serum alkaline phosphatase (IU/L)196 (127.5-502)
Serum 25-OH vitamin D (ng/mL)18.09 ± 9.93
Plasma iPTH (pg/mL)328.10 (143-1111)